BridgeBio Oncology director granted 31,675 stock options

BridgeBio Oncology Therapeutics director Neil Kumar received a stock option grant for 31,675 shares of common stock at an exercise price of $7.73 per share.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics director Neil Kumar received a stock option grant for 31,675 shares of common stock at an exercise price of $7.73 per share. The option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service, and expires in 2036. Following this grant, he holds 31,675 derivative securities directly.

Insider Trade Summary

Grant/Award: 31,675 shares

Grant/Award 1 txn

Insider Kumar Neil

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,675	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,675 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

Option shares granted: 31,675 shares Exercise price: $7.73 per share Underlying common shares: 31,675 shares +2 more

5 metrics

Option shares granted 31,675 shares Stock option grant to director Neil Kumar

Exercise price $7.73 per share Strike price of granted stock options

Underlying common shares 31,675 shares Common stock underlying the stock option

Post-transaction derivative holdings 31,675 derivative securities Total options held after the grant

Option expiration date June 15, 2036 Expiration of the granted stock options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, underlying security, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The shares underlying the stock option vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders regulatory

"the date of the next Annual Meeting of Stockholders of the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Oncology Therapeutics (BBOT) report for Neil Kumar?

Neil Kumar received a stock option grant for 31,675 shares of BridgeBio Oncology Therapeutics common stock. The award is a compensation-related option, not an open-market purchase or sale, and is reported as a derivative acquisition on Form 4.

What is the exercise price of Neil Kumar’s new BBOT stock options?

The granted stock options have an exercise price of $7.73 per share. This means Kumar can buy BridgeBio Oncology Therapeutics common stock at $7.73 once the options vest and are exercised, subject to the option’s terms and expiration date in 2036.

How many BridgeBio Oncology Therapeutics shares are covered by Neil Kumar’s option grant?

The option grant covers 31,675 underlying shares of BridgeBio Oncology Therapeutics common stock. These shares are not issued immediately; they become acquirable if the option vests and Kumar chooses to exercise at the stated $7.73 per-share exercise price.

When do Neil Kumar’s BridgeBio Oncology Therapeutics options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. Vesting is conditioned on Kumar’s continued service to BridgeBio Oncology Therapeutics through the applicable vesting date.

When do Neil Kumar’s BBOT stock options expire?

The reported stock options have an expiration date in 2036, specifically June 15, 2036. If the options are not exercised by that expiration date, the right to purchase the 31,675 underlying shares at $7.73 per share will lapse.

How many derivative securities does Neil Kumar hold after this BBOT option grant?

Following the grant, Neil Kumar holds 31,675 derivative securities directly, corresponding to the newly awarded stock options. This figure reflects his position in this specific option award as reported in the Form 4 filing’s post-transaction holdings column.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.73	06/16/2026		A		31,675		(1)	06/15/2036	Common Stock	31,675	$0	31,675	D

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)